Navigation Links
ADVENTRX Announces Public Offering of Stock
Date:11/10/2011

epartment, 1251 Avenue of the Americas, New York, NY, 10020, telephone: (212) 201-8064 or email: placements@rodm.com.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary product candidates. The Company's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a novel, detergent-free formulation of the chemotherapy drug docetaxel. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding capital-raising and use of proceeds. Actual events or results may differ materially from those expressed or implied by the forward-looking statements in this press release due to a number of risks and uncertainties, including, without limitation: whether or when the offering may be completed; the actual size and terms of the offering; the risk that ADVENTRX is unable to raise sufficient capital to fund development of its product candidates, including its planned phase 3 clinical trials of ANX-188 and ANX-514; the potential for difficulties or delays in reaching agreement with the FDA on the clinical development of ANX-188; the potential for difficulties or delays in completing manufacturing process development activities and manufacturing material for and/or in completing enrollment of the planned phase 3 clinical trials and any other clinical studies; the risks that the pl
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Biosensors Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Analysis of SPIRIT II and SPIRIT III Data Confirms Patients ... Death, a Heart Attack or a ... TAXUS(R) at Two Years, WASHINGTON, Oct. 13 Data ... randomized clinical,trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary ...
... Class, of Stent with Polyzene(R)-F Surface ... for Long-Term,Dual Antiplatelet Therapy, WASHINGTON, ... today,s,"Innovative Devices and Futuristic Therapies" session ... (TCT) scientific,symposium, sponsored by the Cardiovascular ...
Cached Medicine Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 2Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 4Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 512-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4
(Date:7/31/2015)... ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 ... he recalled that his equipment was set up to depict the newly poured concrete. With ... bed. , The photo speaks for itself. Chatfield is also a highly praised safety and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... blog post that encourages the understanding and treatment of ankle sprains. A common ... in-home remedies. This can be dangerous if the condition augments and causes more ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's ... on Thursday, September 17th at Ford Field in Detroit and the second match will ...
(Date:7/31/2015)... ... 31, 2015 , ... everMaya ( http://evermaya.com/ ), a Fashion ... will be named for Madeline Stuart, an 18-year-old model from Brisbane, Australia. Ms. ... with Down syndrome, gracing the front pages of publications across the world. everMaya ...
(Date:7/31/2015)... Detroit, MI (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in conjunction ... by a score of 5-2. Carli Lloyd from the USA team was awarded the ...
Breaking Medicine News(10 mins):Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... 26 Researchers at Wayne State University ... that may one day lead to new treatments.Prostate cancer, ... affects one in six men. In 2008, nearly ... nearly 186,000 were newly diagnosed, and approximately 28,000 died ...
... interactive pediatric healthcare education and resources for hospitals, physicians, and ... ... Wilmington, DE (PRWEB) March 26, 2009 -- Emmi Solutions ... and information programs, and KidsHealth ®, the largest provider ...
... Venture Capital Community to Drive Innovation through Investment Opportunities ... 26 The 510(k) program is under siege from ... complained in a letter to Congress that CDRH management ... 510(k)s. They followed that complaint to Congress with ...
... 26, 2009 Nearly 90 percent of the 700,000 strokes ... a blockage of blood vessels supplying the brain, known ... Catheterization and Cardiovascular Interventions , the official journal of ... solid evidence of the effectiveness of catheter-based therapy (CBT) ...
... a Mayo Clinic study show that a simple, noninvasive finger ... such as a heart attack or stroke, for people who ... study will be presented Tuesday, March 31, 2009 at 11:30 ... Annual Scientific Session in Orlando (0917-7).The noninvasive finger test device, ...
... Sure There,s a Rollover Bar Above Your Head , ... Bloomington, MN ... buyers of previously owned commercial zero-radius-turn (ZRT) mowers to check that each ... to a roll bar on a race car, an overhead ROPS and ...
Cached Medicine News:Health News:Wayne State University Scientists ID New Biomarker for Prostate Cancer 2Health News:Emmi + KidsHealth = Prescription for Informed and Involved Patients 2Health News:Emmi + KidsHealth = Prescription for Informed and Involved Patients 3Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 2Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 3Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 4Health News:Individualized stroke treatment available for patients, though underutilized 2Health News:Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack 2Health News:Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack 3Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 2Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 3Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 4Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: